Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome | Zendy

Talia EldarGeva | Zendy; I. M. Spitz | Zendy; Nigel P. Groome | Zendy; Ehud J. Margalioth | Zendy; Roy Homburg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome

Author(s) -

Talia EldarGeva,

I. M. Spitz,

Nigel P. Groome,

Ehud J. Margalioth,

Roy Homburg

Publication year - 2001

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/16.12.2552

Subject(s) - follistatin , medicine , polycystic ovary , endocrinology , androstenedione , testosterone (patch) , ovary , follicular phase , obesity , body mass index , androgen , insulin resistance , hormone , biology

Activin promotes ovarian follicular development, inhibits androgen production and increases FSH and insulin secretion. Follistatin, an activin-binding protein, neutralizes activin bioactivity. Therefore, a decrease in the ratio of activin/follistatin might encourage characteristic features of polycystic ovary syndrome (PCOS). We investigated whether women with PCOS showed disordered follistatin and/or activin serum concentrations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research